Clinical Trial

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).
Protocol Amendment History 7 changes
notable Trial sites expanded: 197 -> 204 locations 2026-08-07
notable Trial sites expanded: 186 -> 197 locations 2026-07-24
notable Trial sites expanded: 167 -> 186 locations 2026-07-11
notable Trial sites expanded: 156 -> 167 locations 2026-06-19
notable Trial sites expanded: 149 -> 154 locations 2026-05-28
notable Trial sites expanded: 145 -> 149 locations 2026-05-12
notable Trial sites expanded: 129 -> 143 locations 2026-04-16
Trial Details
NCT Number NCT06973187
Lead Sponsor BeOne Medicines
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment 500 participants
Start Date 2025-09-04
Primary Completion 2028-04-17 (estimated)
Study Completion 2028-04-17 (estimated)
Updated on ClinicalTrials.gov 2026-08-06